3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Phase 1
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Melanoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rare Tumour
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Thyroid Gland Carcinoma
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Lobular
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Trastuzumab
303
Paclitaxel
256
Cyclophosphamide
251
Docetaxel
238
Capecitabine
175
Letrozole
163
Carboplatin
163
Doxorubicin
145
Fulvestrant
144
Bevacizumab
121
Anastrozole
106
Tamoxifen
102
exemestane
94
Vinorelbine
91
Epirubicin
90
pertuzumab
88
Gemcitabine
84
Lapatinib
80
Albumin-Bound Paclitaxel
74
Radiotherapy
71
pembrolizumab
70
palbociclib
64
130-nm albumin-bound paclitaxel
58
eribulin
56
Cisplatin
55
Everolimus
49
pyrotinib
44
Taxes
44
Goserelin
43
Neoadjuvant Therapy
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Neoplasms
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled